Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Shareholders alliance. I ask all shareholders to take seriously into consideration this possibility, a large shareholders alliance, to change the Ceo strategy or even to replace the Ceo .
The shareholders are the legal owners of a limited company
Shareholders alliance. I ask all shareholders to take seriously into consideration this possibility, a large shareholders alliance, to change the Ceo strategy or even to replace the Ceo .
The shareholders are the legal owners of a limited company
A honest CEO should step down when not able to control his Company
or the BOD must take action
be ready for a Class Action lawsuit.Likely Culley is trying to take Mast private.
Why not a cut of 90% of the Ceo salary? The same for all management.
Where are their responsibilities if they continue as before?
We need to take control of the company, SHs are the owners Ceo and managers are employees.
All Big Pharma failed in HFpEF. (Heart Failure with Preserved Ejection Fraction)
Also the Pfizer trial completely failed in 2014 to demonstrate the efficacy of Sidenafil (Viagra) in HFpEF, Dr.Bourlag (AIR001 clinical investigator at Mayo) and others demonstrate that Sidenafil may even worsen the HF.
Novartis did the insane mistake to dump Aires when it was at the begin of AIR001 P2a due to a NVS business reorganization.
Merck and Bayer are involved in HFrEF. (Heart Failure with reduced Ejection Fraction) with the drug vericiguat, but with some doubts on efficacy and safety.
Now Novartis has Entresto a combo pill but always for HFrEF,it is effective in particular in the most severe cases.
AIR could be one of the winners in this competition and then a potential blockbuster.
An agreement, something between partnership and buyout, in this so important and empty field of HFpEF shouldn't difficult to achieve.
Obviously for a good CEO...
I agree with you Pray, R/S make sense only for protection against delisting and against the panic selling starting near to 0.06. I agree, Culley is responsible of this situation, for several reasons also because poor communication with SHs.
I'm asking an update of "Ceo Corner" important for this direct communication.
Again, if Culley resigns we'll go at least at the fair value, near $0.50 in 2 days.
Let's hope that Ceo/BoD are finally convinced to sell the Company or at least to secure a strong partnership with a big pharma.
I'm pretty convinced that this will happen, my bet is they are in talks with Novartis.
But with this small and battered Co and in particular with this Ceo/management with a story of failure it would be always better be ready for a lawsuite, only as caution, but retail SHs are so weak alone.
a R/S wouldn't be a tragedy, better now at 0.08 than at 0.19.
I agree about the bad feeling but if we have 8 cent per share of cash now or 0.80 after a 1:10 RS,which is the concrete difference? The pps shouldn't fall from 0.80, or in any case it will recover in few days. If they are in talks for partnership, or to sell EPIC database or even a merger/BO, these operations are made on the capitalization not on the PPS.
How can a stock with this potential and with enough cash for 2 yrs fall under the cash value? This can happen only if there are de-listing concerns.
Ceo should support the PPS when it goes so low without reason.For example, an update of the Ceo Corner on the new scenario can help, it's the lack of presence of the management that is worsening the trend
I agree, Culley behavioral about failed tests seems reprehensible.
Why this complete silence on Vepo data? He wants sell the patients records, really is it the answer? and,how much can he realize?
I think that a so strange result demands explanations. It is unfair vs shareholders that supported the trial also writing on forums and for the patients and the SCD associations.
It's difficult to believe that they didn't some mistake managing EPIC.
Biocrazy ,please, tell us the differences you found in the 2 articles. TIA
surely the Ceo and the management have the full responsibility of the current situation and of the continue depreciation since ANX's time.And furthermore in a public company the shareholders are the owners, that's something which is sometimes forgotten. But I think that a RS now is different from the previous because cash value is the value of the shares and it cannot be further lowered unless for emotional reasons and in any case not permanently,a new dilution will be far worse.
Just mi opinion but I think and hope that the partnership or something bigger will come before this need.
R/S of a stock traded at cash level doesn't change anything unless the listing accomplishment, it could be even positive. A stock pps should be valued by its capitalization and number of shares outstanding .
THe pps is recovered in few days coming back at the cash value.
Culley has several responsibilities but I don't think he is interested in lowering the pps now.
SA article published again, with title a bit different. All right
maybe too bullish for SA style .. maybe it expressed opinions too early about delicate points and potential talks (Big pharma, BO)
just my thought , but pretty strange that it was deleted
Culley should update the Ceo Corner now,a direct less formal communication with shareholders would be appreciate
Great article of SA very informative that everyone should read.
In the article Leny said:"I feel the peak sales of AIR001 for PAH could range from $250 to $339 million."
I think that in the HFpEF the potential sales can even be much greater than in PAH.
I think Novartis is coming back.
They did a huge mistake leaving Aires Ironite (now Mast AIR001) because their current drugs for Heart Failure aren't so good and safe as expected. On opposite Nitrite's pathway appears always more effective and safe also if inhaled. AIR001 appears as a very patient-friendly solution then with a great commercial potential.
If they valuated $250M for Pulmonary Hypertension even more could be for HFpEF.
Just my guess, but ...
very few drugs under test for HFpEF. Despite the huge market composed of several millions of patients in US and UE there aren't drugs approved and very few are tested. I've searched at clinicaltrials.gov and I didn't find any real competitors of AIR001 in HFpEF.
I think AIR001 is a perfect target for big Companies.
Big pharma trials in HF: Merck & Bayer.
They are testing Vericiguat for Heart Failure With Reduced Ejection Fraction (HFrEF) in a very large trial although P2b didn't statistical signif. results.
AIR001 did stat. results in PAH(Pulmonary Hipertension) and in HFpEF Heart Failure With Preserved Ejection Fraction, that represents the 50% cases of HF hospitalization.
If I was MRK or Bayer I wouldn't let the moment go.
It could be, but I hope if Culley decided to speak at this conference he should have something to say.
EPIC, again. What really happened? Trial failed, a fact that seems accepted by all longs also if with huge losses.
But, Sorry, I just can't shake the idea of that the Vepoloxamer results showed. Before the data we were talking about the possible results: if good, average, borderline or too weak to pass,all based on previous P2/P3 trials, on recent studies and articles published at ASH. Against all expectations, including
negative, the data were not only insufficient to pass but also nil and even pejorative vs placebo. Very,very strange.
A so exaggerated bad result that can't be explained with all researchers have been seen for years. I ask what really happened?
Can we with certainty rule out the suspicion of a confuse use of drug and placebo?
unfortunately I have to agree with you. Ceo has also the Ceo corner at Mast's site where he could explain in a less formal way what is happening, maybe asking SHs a bit of patience avoiding strange guesswork. Whereas SHs are the owners of the Co, also if not enough organised
I hope Ceo Culley reads this,just the point of view of a long-standing shareholder. In situations like this when the pps falls perilously, it is important that the company sends out positive signals,some words told with assurance from the Ceo about the stabilization of the situation. E.g. it would be extremely positive hear something about the progress of the new business plan and above all about the promised partnership, also only confirming to be deeply focused on this option.
Then some points about the current fair value of the company,like: the amount of the cash after Hercules, if there is the possibility of new loans, a valuation of the alienable assets but, above all, a valuation of a partnership on AIR001,its minimum value supposed and the market.
That's what we are waiting for you to tell us, not the usual story,it's not the time.
The Ceo corner can be a nice alternative to the PR.
..the CEO is still working there.This is the problem
Lawsuit- Did anyone ANX/MAST EPIC investment think about a CA,lawsuite, Sec report...
Down due to CEO's inability. Today an old fashioned PR, like one before EPIC results.
We are waiting a PR about corporate restructuring, with real numbers,cash,asset,business strategy ....
Culley must leave ASAP,dangerous manager.
not surprised, all biotechs are down 5%,not an easy moment to invest and surely CUlley added another element to his bad reputation and poor reliability. A strong and concrete move is expected, no different alternatives left.
Compliance? Yes, After 30 days below .20 the notification,then 6 months to regain it,and usually there might be also extensions for some reasons.I see it at nasdaq.
IMO a RS is not so important for the Co. now,I don't see real reasons to do it before a corporate restructuring. In any case we are already traded at cashing and much below the fair value then a RS shouldn't modify a lot the valuation, only bad emotionally and useless, a stupid move.
For compliance above 0.20 there are six months
added at 0.097
that would be great,Pray, but sincerely 2 dollars it sounds exaggerate for me.
Maybe Epic database can be worth some millions, the same the patents and if it gave some signs of effectiveness in HF the value can double, then the future trials in stroke and that with the army,other millions. I think Vepo is between 10-30/40 million.
Different valuation for AIR001,much more, but only if the buyer is seriously interested in investing in the cardiological field and has understood the potential of AIR as a blockbuster drug for HF. It actually depends on how good are P2 data.
IMO EPIC data can interest Glycomimetics/Pfizter, same trial in VOC reduction,partially similar antiadesion mechanism
Thank you for share it, pray. I strongly believed in the success of EPIC,you know, based on statistical interim and articles,but something (or everything) went wrong, still incredulous of the differences.
Now let's hope management is able to recover at least a part of the disaster. I hope Culley and management are equal to the situation also doing some personal sacrifices, like some steps down for a good partnership, shares purchases,...
AIR001 seems work, already reached primary endpoint in a P2 in February in HF, soon the second P2 in PAH should give good results, removing the risk of the only-one drug in the pipeline. I don't see imminent risks: no binary events, cash for next 2 years, cuts of the costs. RS for sure if no partnership or poor new loans, this month and the next will be crucial.
AIR001 can become the first inhaler for Heart failure and pulmonary hypertension.Potential bigger success than AFREZZA in diabet.
CEO and insiders must buy shares, this is the shame of this management, never bought shares!
If Ceo Culley has faith in the Mast future and intends remain the CEO should buy shares otherwise is better he steps down.
CEO and insiders must buy shares, this is the shame of this management, never bought shares!
If Ceo Culley has faith in the Mast future and intends remain the CEO should buy shares otherwise is better he steps down.
Traded under cash value. 3 Phase2 ongoing with AIR001 and excellent early data.I now don't see big risks here unless the CEO,let's hope he learned the lesson(s):nevermore alone and nevermore dilutions,maybe also a step down